More than 20 Podium Presentations, Posters and Films to
be Featured
LAVAL, Quebec, April 11, 2018 /CNW/ -- Bausch + Lomb, a leading
global eye health company and wholly owned subsidiary of
Valeant Pharmaceuticals International (NYSE/TSX: VRX), will present
more than 20 new scientific data presentations, including 17 podium
presentations and three posters, at the American Society of
Cataract and Refractive Surgery (ASCRS) Annual Meeting in
Washington, D.C., from
April 13-17, 2018.
"The breadth of data being presented at the ASCRS this year
reinforces our commitment to investing in research across the
Bausch + Lomb business, one of our core therapeutic areas of
focus," said Joseph C. Papa,
chairman and CEO, Valeant. "We are committed to the continued
advancement of our eye health offerings to meet the needs of our
customers and their patients."
A wet lab at the company's booth, as well as educational
programs, will also provide opportunities for surgeons to gain
firsthand experience with, and learn more about, Bausch + Lomb
technologies. These include the company's latest next-generation
platform for cataract and retina surgery, Stellaris Elite™ vision
enhancement system, the VICTUS® femtosecond laser for
advanced cataract and corneal applications, and its broad selection
of intraocular lenses (IOLs) and delivery systems, including the
new enVista® MX60E with StableFlex™ technology.
The full schedule research to be presented includes:
Saturday, April 14
- Sheppard, John D. "Thirty-Six Month Clinical Experience with
a Hydrophobic Acrylic IOL in Patients with Endothelial Compromise
Undergoing Simultaneous Cataract Extraction and DSEK."
Saturday, April 14 at 4:15 p.m.; Level 1, Room 144C
- Shultz, Mitchell C. "Analysis of Optical Aberrations and
Depth of Focus Using a Ray-Tracing Analyzer in Patients with Zero
Spherical Aberration IOLs." Saturday,
April 14 at 1:07 p.m.; Level
1, Room 143B
Sunday, April 15
- Koch, Douglas D. "Evaluation of a New Phacoemulsification
Infusion System." Sunday, April 15 at 3:25 p.m.; Level 1, Room 143B
- McCabe, Cathleen M. "Phaco Energy Profile of Various Nuclear
Disassembly Techniques in the Setting of Adaptive Fluidics."
Sunday, April 15 at 3:02 p.m.; Level 1, Room 143B
- McCabe, Cathleen M. "Intraoperative Evaluation of New
Vacuum-Based Phaco System with Adaptive Fluidics." Sunday, April 15 at 3:45
p.m.; Level 1, Room 143B
- Packer, Mark. "Comparison of Spectacle Independence for a
New Toric Intraocular Lens (IOL) versus Predicate Spherical
IOL." Sunday, April 15 at
8:51 a.m.; Level 1, Room 143A
- Packer, Mark. "Modeling the Effect of Off-Axis Light for
Refractive and Diffractive IOLs." Sunday, April 15 at 8:45
a.m.; Level 1, Room 143C
- Shultz, Mitchell C. "Comparative Analysis of Dual Linear
Phacoemulsification Using New Adaptive Fluidics System in
Femtosecond-Assisted and Traditional Cataract Surgery."
Sunday, April 15 at 3:07 p.m.; Level 1, Room 143B
- Shultz, Mitchell C. "Comparative Analysis of Dual Linear
Phacoemulsification with New Adaptive Fluidics System in
Traditional Phacoemulsification of Various Nuclear Densities."
Sunday, April 15 at 3:17 p.m.; Level 1, Room 143B
Monday, April 16
- Jackson, Mitchell A. "Advantages of Multiburst Phaco
Modality in Femtosecond Laser-Assisted Cases." Monday, April 16 at 3:41
p.m.; Level 1, Room 143A
- Liang, Eva I. "Comparison of Visual Outcomes of a Toric
Accommodating IOL and a Toric Extended-Depth-of Focus IOL."
Monday, April 16 at 8:17 a.m.; Level 1, Room 143B
- Liang, Eva I. "Patient Selection and Comparison of Visual
Outcomes of an Accommodating IOL and an Extended-Depth-of-Focus
IOL." Monday, April 16 at
8:43 a.m.; Level 1, Room 143B
- Sheppard, John D. "Twelve-Month Clinical Experience with a
Hydrophobic Acrylic IOL in Patients at Risk for Intraocular
Inflammation." Monday, April 16
at 3:12 p.m.; Level 1, Room 143C
- Vittitow, Jason L. "Efficacy and Safety of a Novel Submicron
Corticosteroid Formulation in the Treatment of Inflammation and
Pain Post-Cataract Surgery." Monday,
April 16 at 1:46 p.m., Level
1, Room 143B
Tuesday, April 17
- Rowen, Sheri L. "Surgical Outcomes for Accommodative
Intraocular Lens (IOL) in Patients with Highly Aberrated
Corneas." Tuesday, April 17 at
11:08 a.m.; Level 1, Room 143C
- Stephenson, P. Dee G. "Clinical Evaluation of a New Material
for Hydrophobic Acrylic IOL." Tuesday,
April 17 at 11:03 a.m.; Level
1, Room 144B
- Whitman, Jeffrey. "Postoperative Aberration Profile After
Implantation of Hinged, Plate-Haptic Accommodating IOL."
Tuesday, April 17 at 10:51 a.m.; Level 1, Room 143C
Posters
- Lu, Kenneth. "Using Pattern ERG to Objectively Measure
Contrast Sensitivity in Pseudophakes with Different IOLs."
Poster available Saturday, April 14
to Tuesday, April 17
- O'Brien, Terrence P. "Manual versus Femtosecond Corneal
Incisions." Poster available Saturday,
April 14 to Tuesday, April
17
- Singh, Inder P. "Topology Verification of
Femtosecond-Created Capsulorhexis and Arcuate Incisions Using
Intraoperative Guidance System." Poster available Saturday, April 14 to Tuesday, April 17
Films
- Shultz, Mitchell C. "Adaptive Fluidics in Femtosecond
Laser–Assisted Cataract Surgery." Film available Saturday, April 14 to Tuesday, April 17
About Bausch + Lomb
Bausch + Lomb, a Valeant
Pharmaceuticals International, Inc. company, is a leading global
eye health organization that is solely focused on protecting,
enhancing and restoring people's eyesight. Its core businesses
include over-the-counter supplements, eye care products, ophthalmic
pharmaceuticals, contact lenses, lens care products, ophthalmic
surgical devices and instruments. Bausch + Lomb develops,
manufactures and markets one of the most comprehensive product
portfolios in the industry, which is available in more than 100
countries.
About Valeant
Valeant Pharmaceuticals International,
Inc. (NYSE/TSX: VRX) is a global company whose mission is to
improve people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.valeant.com.
Forward-looking Statements
This news release may
contain forward-looking statements which may generally be
identified by the use of the words "anticipates," "expects,"
"intends," "plans," "should," "could," "would," "may," "will,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks and uncertainties discussed in Valeant's most
recent annual or quarterly report and detailed from time to time in
Valeant's other filings with the Securities and Exchange Commission
and the Canadian Securities Administrators, which factors are
incorporated herein by reference. Readers are cautioned not to
place undue reliance on any of these forward-looking statements.
These forward-looking statements speak only as of the date hereof.
Valeant undertakes no obligation to update any of these
forward-looking statements to reflect events or circumstances after
the date of this news release or to reflect actual outcomes, unless
required by law.
®/™ are trademarks of Bausch & Lomb Incorporated or its
affiliates. Any other product/brand names are trademarks of the
respective owners.
© 2018 Bausch & Lomb Incorporated.
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@valeant.com
|
lainie.keller@valeant.com
|
(514)
856-3855
|
(908)
927-0617
|
(877) 281-6642 (toll
free)
|
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/bausch--lomb-to-showcase-new-scientific-data-during-the-annual-meeting-of-the-american-society-of-cataract-and-refractive-surgery-300627907.html
SOURCE Valeant Pharmaceuticals International, Inc.